C. Zielinski

发表

Chromosomal abnormalities of young multiple myeloma patients (<45 yr) are not different from those of other age groups and are independent of stage according to the International Staging System

H. Kaufmann, J. Ackermann, H. Gisslinger, 2007, European journal of haematology.

Glutathione in the prevention of cisplatin induced toxicities. A prospectively randomized pilot trial in patients with head and neck cancer and non small cell lung cancer.

G. Steger, W. Oder, C. Wenzel, 2000, Wiener klinische Wochenschrift.

Both IGH translocations and chromosome 13q deletions are early events in monoclonal gammopathy of undetermined significance and do not evolve during transition to multiple myeloma

U. Jäger, R. Wieser, H. Kaufmann, 2004, Leukemia.

Doubling epirubicin dose intensity ( 100 mg / m 2 versus 50 mg / m 2 ) in the FEC regimen significantly increases response rates . An international randomised phase III study in metastatic breast cancer

G. Brufman, A. Martoni, E. Colajori, 2004 .

Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion

R. Wieser, H. Kaufmann, J. Ackermann, 2007, Leukemia.

Mesenchymal stem cells in patients with chronic myelogenous leukaemia or bi-phenotypic Ph+ acute leukaemia are not related to the leukaemic clone.

U. Jaeger, P. Valent, C. Sillaber, 2007, Anticancer research.

Adverse event management in patients with advanced cancer receiving oral everolimus: focus on breast cancer

M. Gnant, H. Zwierzina, A. Awada, 2014 .

EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours.

N. Kearney, G. Lyman, M. Aapro, 2006, European journal of cancer.

Sequential Administration of Interferon-&ggr;, GM-CSF, and Interleukin-2 in Patients With Metastatic Renal Cell Carcinoma: Results of a Phase II Trial

G. Kramer, M. Marberger, G. Steger, 2001, Journal of immunotherapy.

2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.

N. Kearney, G. Lyman, M. Aapro, 2011, European journal of cancer.

Beneficial effect of high-dose chemotherapy in multiple myeloma patients with unfavorable prognostic features.

H. Kaufmann, J. Ackermann, H. Gisslinger, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Humoral and cellular immune responses and their kinetics vary in dependence of diagnosis and treatment in immunocompromised patients upon COVID-19 mRNA vaccination.

W. Reinisch, G. Novacek, G. Tajti, 2021, medRxiv.

Capecitabine in the treatment of metastatic renal cell carcinoma failing immunotherapy.

G. Kramer, M. Marberger, G. Steger, 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[Results of cyclosporin A therapy in the early phase of type I diabetes mellitus].

G. Schernthaner, C. Müller, S. Gaube, 1988, Wiener klinische Wochenschrift.

ESMO-Magnitude of Clinical Benefit Scale for Haematological Malignancies (ESMO-MCBS:H) Version 1.0.

M. Piccart, B. Gyawali, U. Dafni, 2023, Annals of oncology : official journal of the European Society for Medical Oncology.

Global sequence diversity of BRCA2: analysis of 71 breast cancer families and 95 control individuals of worldwide populations.

P. Underhill, P. Shen, P. Oefner, 1999, Human molecular genetics.